- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Mostafa Kamal Named Prime Therapeutics' President and CEO
The Magellan Rx Management CEO is replacing Ken Paulus, who held the top job at Prime since May 2019.
Mostafa Kamal is the new president and CEO of Prime Therapeutics, a pharmacy benefits manager heaquartered in the suburban Twin Cities and owned by 19 Blues plans.
Prime Therapeutics announced today that Mostafa Kamal, the chief executive officer of Magellan Rx Management, the specialty drug company that Prime purchased last year for $1.35 billion, will succeed Ken Paulus as president and CEO of pharmacy benefit management (PBM) company.
"Mostafa's vision for what we can become is inspiring and bold," Maurice Smith, Prime's board chairman,said in a press release. "As Prime seeks to reimagine pharmacy benefit management, he is the right person to build on the strong foundation Ken leaves as he retires."
Kamal is taking the reins at Prime as PBMs have come under increasing scrutiny. The Federal Trade Commission has launched an inquiry into the industry, and several bills have been introduced in Congress that would increase regulation and oversight of PBMs. In addition, many states have passed laws curbing PBM practices, such as spread pricing.
Prime, which is owned by 19 Blues plans, is not among the “big three” PBMs — Optum Rx, CVS Caremark and Express Scripts — that dominate the industry and have received most of attention and criticism from lawmakers. However, Prime entered into a three-year collaborative agreement with Express Scripts in late 2019, shortly after Paulus took over the leadership role. A company spokesperson said today that Prime has renewed the Express Scripts collaboration.
Related: PBM Leaders: A Conversation with Ken Paulus, CEO and President of Prime Therapeutics, Part 1
"I leave Prime in capable hands," Paulus said in the company press release about Kamal’s promotion. “Leading this company for the past four years has been a true privilege. I’m proud of the work we have done together to provide the kind of care we’d want for our loved ones. I know Prime will continue to thrive under Mostafa’s leadership.”
The company’s announcement quotes Kamal as saying that the newly combined organization (of Prime with Magellan) “has the right solutions, scale and know-how to be a powerful player in this market.”
Prior to Magellan, Kamal worked for Medco Health Solutions, which was acquired by Express Scripts in 2011, and for Hertz, according to his LinkedIn page. He has bachelor's degree from Rutgers University, majoring in business economics, says his LinkedIn page.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
